{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:31:01Z","timestamp":1792855861458,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK035B"],"award-info":[{"award-number":["02NUK035B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK076E"],"award-info":[{"award-number":["02NUK076E"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK032"],"award-info":[{"award-number":["02NUK032"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["02NUK035B"],"award-info":[{"award-number":["02NUK035B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Cancer Aid (DKH), Mildred-Scheel Cancer Career Center, HaTRiCS4 Program"},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 337\/16-1"],"award-info":[{"award-number":["INST 337\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 152\/837-1"],"award-info":[{"award-number":["INST 152\/837-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 152\/947-1 FUGG"],"award-info":[{"award-number":["INST 152\/947-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 337\/15-1"],"award-info":[{"award-number":["INST 337\/15-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 337\/16-1"],"award-info":[{"award-number":["INST 337\/16-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 152\/837-1"],"award-info":[{"award-number":["INST 152\/837-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 152\/947-1 FUGG"],"award-info":[{"award-number":["INST 152\/947-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two PARP inhibitors (PARPis), olaparib and talazoparib, have been approved in combination with androgen receptor pathway inhibitors (ARPIs) for metastatic castration-resistant prostate cancer (mCRPC) in Europe, regardless of homologous-recombination repair (HRR) status. However, the mechanism in HRR-negative patients remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed PARP inhibitors (PARPis; olaparib, talazoparib) alone and with ARPIs (abiraterone, enzalutamide, apalutamide) in prostate cancer cell lines, metastatic patient-derived organoids (mPDOs), and LN-metastatic tissue slice cultures. HRDetect and multi-omics analyses were used to investigate response mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PARPi-ARPI combinations significantly reduced survival in LNCaP, DU145, and 22RV1 cells and produced greater cytotoxicity than either agent alone in all models. In three metastatic mPDOs, olaparib alone had no effect, whereas talazoparib reduced survival in one mPDO and ARPIs reduced survival in two. In all tested models, PARPi-ARPI combinations produced greater cytotoxicity than either agent alone. None of the mPDOs showed BRCAness by HRDetect. ARPIs downregulated RAD51 and induced a BRCAness-like state, with reduced RAD51 foci formation at DNA double-strand break sites and impaired repair capacity, thereby sensitizing cells to PARPis. In LN-metastatic tissue slice cultures, combination therapy reduced double-strand break repair capacity in 67% of samples. Proteomic analysis showed that olaparib suppressed prometastatic pathways, including epithelial-mesenchymal transition and angiogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ARPIs induce a BRCAness-like phenotype through RAD51 downregulation and enhance PARPi sensitivity in metastatic prostate cancer models, supporting combined ARPI-PARPi therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03518-7","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:02:32Z","timestamp":1783436552000},"page":"1140-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status"],"prefix":"10.1038","volume":"135","author":[{"given":"Mohamed E.","family":"Elsesy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayham","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Jung","family":"Oh-Hohenhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5993-7709","authenticated-orcid":false,"given":"Malik","family":"Alawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Siebels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3840-2844","authenticated-orcid":false,"given":"Susanne","family":"Burdak-Rothkamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Schl\u00fcter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rothkamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0641-2885","authenticated-orcid":false,"given":"Wael Y.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"3518_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3518_CR2","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.2147\/OTT.S117176","volume":"9","author":"AS Merseburger","year":"2016","unstructured":"Merseburger AS, Alcaraz A, von Klot CA. Androgen deprivation therapy as backbone therapy in the management of prostate cancer. Onco Targets Ther. 2016;9:7263\u201374.","journal-title":"Onco Targets Ther"},{"key":"3518_CR3","first-page":"742","volume":"3","author":"S Verma","year":"2020","unstructured":"Verma S, Prajapati KS, Kushwaha PP, Shuaib M, Kumar Singh A, Kumar S, et al. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. Cancer Drug Resist. 2020;3:742\u201361.","journal-title":"Cancer Drug Resist"},{"key":"3518_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.clon.2014.02.007","volume":"26","author":"R Plummer","year":"2014","unstructured":"Plummer R. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside. Clin Oncol. 2014;26:250\u20136.","journal-title":"Clin Oncol"},{"key":"3518_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12388-2","volume":"24","author":"Q Zhu","year":"2024","unstructured":"Zhu Q, Chen J, Liu H, Zhao J, Xu C, Sun G, et al. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and Bayesian network meta-analysis. BMC Cancer. 2024;24:706.","journal-title":"BMC Cancer"},{"key":"3518_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, Lorente D, Alameda D, Cattrini C, Romero-Laorden N, Lozano R, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35:458\u201372.","journal-title":"Ann Oncol"},{"key":"3518_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9456020","volume":"2017","author":"E Olokpa","year":"2017","unstructured":"Olokpa E, Moss PE, Stewart LV. Crosstalk between the androgen receptor and PPAR gamma signaling pathways in the prostate. PPAR Res. 2017;2017:9456020.","journal-title":"PPAR Res"},{"key":"3518_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241258443","volume":"16","author":"M Garofoli","year":"2024","unstructured":"Garofoli M, Maiorano BA, Bruno G, Giordano G, Di Tullio P, Maselli FM, et al. Androgen receptor, PARP signaling, and tumor microenvironment: the \u2018perfect triad\u2019 in prostate cancer? Ther Adv Med Oncol. 2024;16:17588359241258443.","journal-title":"Ther Adv Med Oncol"},{"key":"3518_CR9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.3390\/genes10080565","volume":"10","author":"V Virtanen","year":"2019","unstructured":"Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M. PARP inhibitors in prostate cancer\u2013the preclinical rationale and current clinical development. Genes. 2019;10:565.","journal-title":"Genes"},{"key":"3518_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3:1245\u201353.","journal-title":"Cancer Discov"},{"key":"3518_CR11","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"3518_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402:291\u2013303.","journal-title":"Lancet"},{"key":"3518_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/cancers12092467","volume":"12","author":"ME Elsesy","year":"2020","unstructured":"Elsesy ME, Oh-Hohenhorst SJ, L\u00f6ser A, Oing C, Mutiara S, K\u00f6cher S, et al. Second-generation antiandrogen therapy radiosensitizes prostate cancer regardless of castration state through inhibition of DNA double strand break repair. Cancers. 2020;12:9.","journal-title":"Cancers"},{"key":"3518_CR14","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1126\/science.abl9283","volume":"376","author":"A Degasperi","year":"2022","unstructured":"Degasperi A, Zou X, Amarante TD, Martinez-Martinez A, Koh GCC, Dias JML, et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science. 2022;376:6591.","journal-title":"Science"},{"key":"3518_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s43018-020-0027-5","volume":"1","author":"A Degasperi","year":"2020","unstructured":"Degasperi A, Amarante TD, Czarnecki J, Shooter S, Zou X, Glodzik D, et al. A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies. Nat Cancer. 2020;1:249\u201363.","journal-title":"Nat Cancer"},{"key":"3518_CR16","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884\u2013i90.","journal-title":"Bioinformatics"},{"key":"3518_CR17","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754\u201360.","journal-title":"Bioinformatics"},{"key":"3518_CR18","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics. 2009;25:2078\u20139.","journal-title":"Bioinformatics"},{"key":"3518_CR19","doi-asserted-by":"crossref","unstructured":"Park J, Cook DE, Chang PC, Kolesnikov A, Brambrink L, Mier JC, et al. DeepSomatic: Accurate somatic small variant discovery for multiple sequencing technologies. bioRxiv. 2024.","DOI":"10.1101\/2024.08.16.608331"},{"key":"3518_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"3518_CR21","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, K\u00e4llberg M, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32:1220\u20132.","journal-title":"Bioinformatics"},{"key":"3518_CR22","doi-asserted-by":"publisher","first-page":"16910","DOI":"10.1073\/pnas.1009843107","volume":"107","author":"P Van Loo","year":"2010","unstructured":"Van Loo P, Nordgard SH, Lingj\u00e6rde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 2010;107:16910\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3518_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22289-7","volume":"8","author":"WY Mansour","year":"2018","unstructured":"Mansour WY, Tennstedt P, Volquardsen J, Oing C, Kluth M, Hube-Magg C, et al. Loss of PTEN-assisted G2\/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. Sci Rep. 2018;8:3947.","journal-title":"Sci Rep"},{"key":"3518_CR24","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/ijc.32018","volume":"144","author":"S K\u00f6cher","year":"2019","unstructured":"K\u00f6cher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, et al. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer. Int J Cancer. 2019;144:1685\u201396.","journal-title":"Int J Cancer"},{"key":"3518_CR25","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/1878-0261.13382","volume":"17","author":"ME Elsesy","year":"2023","unstructured":"Elsesy ME, Oh-Hohenhorst SJ, Oing C, Eckhardt A, Burdak-Rothkamm S, Alawi M, et al. Preclinical patient-derived modeling of castration-resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease. Mol Oncol. 2023;17:1129\u201347.","journal-title":"Mol Oncol"},{"key":"3518_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"3518_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17:41\u20134.","journal-title":"Nat Methods"},{"key":"3518_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods. 2016;13:731\u201340.","journal-title":"Nat Methods"},{"key":"3518_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with Enrichr. Curr Protoc. 2021;1:e90.","journal-title":"Curr Protoc"},{"key":"3518_CR30","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3518_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 2013;14:128.","journal-title":"BMC Bioinforma"},{"key":"3518_CR32","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/1878-0261.12185","volume":"12","author":"GE Feiersinger","year":"2018","unstructured":"Feiersinger GE, Trattnig K, Leitner PD, Guggenberger F, Oberhuber A, Peer S, et al. Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells. Mol Oncol. 2018;12:561\u201376.","journal-title":"Mol Oncol"},{"key":"3518_CR33","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.febslet.2006.03.041","volume":"580","author":"F Alimirah","year":"2006","unstructured":"Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett. 2006;580:2294\u2013300.","journal-title":"FEBS Lett"},{"key":"3518_CR34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"3518_CR35","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1158\/0008-5472.CAN-19-3020","volume":"81","author":"GD Barnabas","year":"2021","unstructured":"Barnabas GD, Lee JS, Shami T, Harel M, Beck L, Selitrennik M, et al. Serine biosynthesis is a metabolic vulnerability in IDH2-driven breast cancer progression. Cancer Res. 2021;81:1443\u201356.","journal-title":"Cancer Res"},{"key":"3518_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1164067","volume":"14","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Diao L, Zhang C, Wang F, Guan X, Yao X. Use of PARP inhibitors in prostate cancer: from specific to broader application. Front Endocrinol (Lausanne). 2023;14:1164067.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3518_CR37","doi-asserted-by":"crossref","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10.","DOI":"10.1126\/scisignal.aam7479"},{"key":"3518_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134\u201349.","journal-title":"Cancer Discov"},{"key":"3518_CR39","doi-asserted-by":"publisher","first-page":"14573","DOI":"10.1073\/pnas.1908547116","volume":"116","author":"B Gui","year":"2019","unstructured":"Gui B, Gui F, Takai T, Feng C, Bai X, Fazli L, et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc Natl Acad Sci USA. 2019;116:14573\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3518_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-49651-0_1","volume":"198","author":"K Borgmann","year":"2016","unstructured":"Borgmann K, K\u00f6cher S, Kriegs M, Mansour WY, Parplys AC, Rieckmann T, et al. DNA Repair. Recent Results Cancer Res. 2016;198:1\u201324.","journal-title":"Recent Results Cancer Res"},{"key":"3518_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nm.4292","volume":"23","author":"H Davies","year":"2017","unstructured":"Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med. 2017;23:517\u201325.","journal-title":"Nat Med"},{"key":"3518_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00427-8","volume":"10","author":"M Oshi","year":"2022","unstructured":"Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, et al. Development of a novel BRCAness score that predicts response to PARP inhibitors. Biomark Res. 2022;10:80.","journal-title":"Biomark Res"},{"key":"3518_CR43","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","volume":"3","author":"JF Goodwin","year":"2013","unstructured":"Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013;3:1254\u201371.","journal-title":"Cancer Discov"},{"key":"3518_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374.","journal-title":"Nat Commun"},{"key":"3518_CR45","doi-asserted-by":"publisher","first-page":"ra47","DOI":"10.1126\/scisignal.2005070","volume":"7","author":"L Li","year":"2014","unstructured":"Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, et al. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014;7:ra47.","journal-title":"Sci Signal"},{"key":"3518_CR46","doi-asserted-by":"publisher","first-page":"CT018","DOI":"10.1158\/1538-7445.AM2024-CT018","volume":"84","author":"JM Piulats","year":"2024","unstructured":"Piulats JM, Azad AA, Laird AD, Matsubara N, Fizazi K, Shore ND, et al. Abstract CT018: TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Cancer Res. 2024;84:CT018 CT.","journal-title":"Cancer Res"},{"key":"3518_CR47","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ccr.2011.04.010","volume":"19","author":"JC Brenner","year":"2011","unstructured":"Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell. 2011;19:664\u201378.","journal-title":"Cancer Cell"},{"key":"3518_CR48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms21239176","volume":"21","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Yam JC, Tham CC, Pang CP, Chu WK. RB regulates DNA double strand break repair pathway choice by mediating CtIP dependent end resection. Int J Mol Sci. 2020;21:23.","journal-title":"Int J Mol Sci"},{"key":"3518_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","volume":"42","author":"MHA Hussain","year":"2024","unstructured":"Hussain MHA, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, et al. BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm). J Clin Oncol. 2024;42:19.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03518-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:14:06Z","timestamp":1789474446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03518-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10,5]]}},"alternative-id":["3518"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03518-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the local ethics committee [Ethik-Kommission der \u00c4rztekammer Hamburg], under project number PV7007. All procedures adhered to the Declaration of Helsinki, and written informed consent was obtained from all participants.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}